TY  - JOUR
AU  - Prüß, Harald
TI  - Autoantibodies in neurological disease.
JO  - Nature reviews / Immunology
VL  - 21
IS  - 12
SN  - 1474-1741
CY  - London
PB  - Nature Publ. Group
M1  - DZNE-2021-00746
SP  - 798-813
PY  - 2021
AB  - The realization that autoantibodies can contribute to dysfunction of the brain has brought about a paradigm shift in neurological diseases over the past decade, offering up important novel diagnostic and therapeutic opportunities. Detection of specific autoantibodies to neuronal or glial targets has resulted in a better understanding of central nervous system autoimmunity and in the reclassification of some diseases previously thought to result from infectious, 'idiopathic' or psychogenic causes. The most prominent examples, such as aquaporin 4 autoantibodies in neuromyelitis optica or NMDAR autoantibodies in encephalitis, have stimulated an entire field of clinical and experimental studies on disease mechanisms and immunological abnormalities. Also, these findings inspired the search for additional autoantibodies, which has been very successful to date and has not yet reached its peak. This Review summarizes this rapid development at a point in time where preclinical studies have started delivering fundamental new data for mechanistic understanding, where new technologies are being introduced into this field, and - most importantly - where the first specifically tailored immunotherapeutic approaches are emerging.
KW  - Animals
KW  - Aquaporin 4: immunology
KW  - Autoantibodies: immunology
KW  - Autoimmunity
KW  - Brain: immunology
KW  - Brain: physiopathology
KW  - Encephalitis: immunology
KW  - Encephalitis: physiopathology
KW  - Encephalitis: therapy
KW  - Humans
KW  - Neuromyelitis Optica: immunology
KW  - Neuromyelitis Optica: physiopathology
KW  - Neuromyelitis Optica: therapy
KW  - Receptors, N-Methyl-D-Aspartate: immunology
LB  - PUB:(DE-HGF)16
C6  - pmid:33976421
C2  - pmc:PMC8111372
DO  - DOI:10.1038/s41577-021-00543-w
UR  - https://pub.dzne.de/record/155568
ER  -